|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Management of digestive bleeding related to portal hypertension in cirrhotic patients:A French multicenter cross-sectional practice survey显示文摘AIM: To investigate the conformity of management practices of gastrointestinal hemorrhage in cirrhotic patients with relevant guidelines. METHODS: A questionnaire on the management of digestive bleeding was completed for all consecutive cirrhotic patients admitted to 31 French hospitals. RESULTS: One hundred and twenty-six bleeding events were recorded. It was the first bleeding episode in 79 patients (63%), of whom 40 (51%) had a prior diagnosis of cirrhosis and 25 (32%) had previously undergone an endoscopy. The bleeding episode was a recurrence in 46 patients (37%). The median time between onset and admission was 4 h, but exceeded 12 h in 42% of cases. There was an agreement between centers forearly vasoactive drug administration (87% of cases), association with ligation (42%) more often than sclerosis (21%) at initial endoscopy, and antibiotic prophylaxis (64%). By contrast, prescription of beta-blockade alone or in combination (0 to 100%, P = 0.003) for secondary prophylaxis and lactulose (26% to 86%, P = 0.04), differed among centers. CONCLUSION: In French hospitals, management of bleeding related to portal hypertension in cirrhotic patients is generally in keeping with the consensus. Broad variability still remains concerning beta-blockade use for secondary prophylaxis. Screening for esophageal varices, the use of antibiotic prophylaxis and patients information need to be improved. | Pierre Ingrand Jérme Gournay Pierre Bernard Frédéric Oberti Brigitte Bernard-Chabert Arnault Pauwels Philippe Renard Eric Bartoli Jean-Franois Cadranel Jean-Claude Barbare Isabelle Ingrand Michel Beauchant | 2006 | World Journal of Gastroenterology2006，12，48： | 4 |
| 2 | Lessons from “real life experience” of rifaximin use in the management of recurrent hepatic encephalopathy显示文摘BACKGROUND Hepatic encephalopathy(HE)is a major complication of cirrhosis with independent prognostic significance.The current management of HE is mainly based on lactulose.Rifaximin has been shown to decrease the risk of HE recurrence in patients with episodic forms.HE can also be persistent.However,there is no drug support recommendation for rifaximin use in this setting.AIM To assess the effectiveness of rifaximin in the management of recurrent episodes of HE and recurrent acute exacerbations on persistent HE,in“real life conditions”.METHODS In this retrospective study,using a within-subjects design,we collected data of patients treated with rifaximin for HE in two liver diseases centers,during the six-month period before and during the six-month period after the initiation of rifaximin.The primary effectiveness endpoint was the total number of HE events involving hospitalization.RESULTS Rifaximin was introduced for prevention of recurrent HE episodes in 29 out of 62 patients with normal mental status between episodes and for prevention of recurrent acute exacerbations on persistent HE in 33 out of 62 patients.In the“prevention of recurrent HE episodes”group,fewer HE events(0.79 vs 1.78;P=0.013)were reported during the period of time when rifaximin was used.In the“prevention of recurrent acute exacerbations on persistent HE”group,there was no significant difference in the number of HE-events(1.48 vs 1.77;P=0.582).CONCLUSION In this real-life experience,the effectiveness of rifaximin was confirmed in the prevention of HE episodes recurrence but was not proved in the prevention of acute exacerbations recurrence on persistent HE. | Fiona Chautant Maeva Guillaume Marie-Angèle Robic Jean-François Cadranel Jean-Marie Peron Hortensia Lison Charlène Cool Christophe Bureau Véronique Duhalde | 2020 | World Journal of Hepatology2020，12，1： | 3 |
| 3 | Evidence-based Guidelines From ESPGHAN and NASPGHAN for Helicobacter pylori Infection in Children显示文摘 | Sibylle Koletzko Nicola L. Jones Karen J. Goodman Benjamin Gold Marion Rowland Samy Cadranel Sonny Chong Richard B. Colletti Thomas Casswall Yoram Elitsur Jeannette Guarner Nicolas Kalach Armando Madrazo Francis Megraud Giuseppina Oderda | 2011 | Journal of Pediatric Gastroenterology and Nutrition2011，，2： | 2 |
| 4 | Practices of Liver Biopsy in France: Results of a Prospective Nationwide Survey显示文摘 | Jean-Fran?ois Cadranel Pierre Rufat Fran?oise Degos | 2000 | Hepatology2000，，3： | 2 |
| 5 | Afatinib versus placebo for patients with advanced ,metastatic non-small- cell lung cancer after failure of erlotinib,gefitinib,or both,and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial 显示文摘 | Miller VA Hirsh V Cadranel J | 2012 | Lancet Oncol2012，13，5： | 1 |
| 6 | Clonality analysis of alveolar B lymphocytes contributes to the diagnostic strategy in clinical suspicion of pulmonary lymphoma 显示文摘 | Zompi S Coudre U Cadranel J | 2004 | Blood2004，103，8： | 1 |
| 7 | Primary pulmonary lymphoma显示文摘 | Cadranel J Wislez M Antoine M | 2002 | Eur Respir J2002，20，： | 1 |
| 8 | Cost-effectiveness of three strategies for second-line erlotinib initiation in non small-cell lung cancer:the ERMETIC study part 3显示文摘 | Chouaid C Borget I Cadranel J | 2012 | Eur Respir J2012，39，1： | 1 |
| 9 | IFCT0401 trial: Phase Ⅱ study of gefitinib administered as first line treatment in non-re-seetable, pneumonie-type adenocarcinoma (P-ADC)显示文摘 | Cadranel J Quoix E Debove P | 2006 | Proc Am Soc Clin Oncol2006，25，： | 1 |
| 10 | Practices of liver biopsy in France : results of a prospective nationwide survey, for the group of epidemi- ology of the French association for the study of the liver (AFEF) 显示文摘 | Cadranel JF Rufat P Degos F | 2000 | Hepatology2000，32，3： | 1 |
| 11 | Lymphoma of pulmonary mucosa-assocated lymphoid tissue:CT scan findings and pathological correlations显示文摘 | Wislez M Cadranel J Antoine M | 1999 | Eur Respir J1999，14，2： | 1 |
| 12 | Computed tomographic diag- nosis of bronchogenic carcinoma in HIV-infected patients 显示文摘 | Bazot M Cadranel J Khalil A | 2000 | Lung Cancer2000，28，3： | 1 |
| 13 | A persistent challenge: the diagnosis of respiratory disease in the non AIDS immunocompromised host 显示文摘 | Mayaud C Cadranel J | 2000 | Thorax2000，55，6： | 1 |
| 14 | Afatinib versus placebo far patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefiinib, or both, and one or two lines of chemo- therapy ( LUX-Lung 1 ) : a phase 2b/3 randomised trial显示文摘 | Miller VA Hirsh V Cadranel J | 2012 | Lancet Onco12012，13，5： | 1 |
| 15 | Pulmonary AIDS-related lymphoma radiographic and CT findings 显示文摘 | Bazot M Cadranel J Benayoun S | 1999 | Chest1999，116，5： | 1 |
| 16 | IFCT0401 trial: Phase Ⅱ study of gefitinib administered as first line treatment in non-resectable, pneumonic-type adenocarcinoma (P-ADC) 显示文摘 | CADRANEL J QUOIX E DEBOVE P | 2006 | J Clin Oncol2006，24，18： | 1 |
| 17 | Bronchoalveolar Carcinoma显示文摘 | Wislez M Cadranel J Milleron B | 2003 | Rev Prat2003，53，7： | 1 |
| 18 | Toxoplasma gondii pneumonia in patients with the acquired immunodeficiency syndrome 显示文摘 | Oksenhendler E Cadranel J Sarfati C | 1990 | Am J Med1990，88，5： | 1 |
| 19 | Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial显示文摘 | MILLER V A HIRSH V CADRANEL J | 2012 | Lancet Oncol2012，13，5： | 1 |
| 20 | Toxoplasma gondiipneumonia in patients -with the acquired immunodeficiency syndrome显示文摘 | Oksenhendler E Cadranel J Sarfati C | 1990 | AmJMed1990，88，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员